Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
QL

WKN: A41DDP | ISIN: SE0025420714 | Ticker: 3F80
Frankfurt
20.11.26 | 08:26
0,994 Euro
-8,81 % -0,096
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
Q-LINEA AB Chart 1 Jahr
5-Tage-Chart
Q-LINEA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,9061,08017:13

Aktuelle News zur Q-LINEA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
30.10.Q-linea AB Q3 Loss Declines1
30.10.Q-Linea AB: Interim Report January 1 - September 30 2026146US moving forward on expanded ASTar® panel Third quarter 2026 (July - September)• Contracted ASTar instruments 3 (5)• Net sales MSEK 4.8 (3.5)• Consumables sales per instrument (R12) TSEK 247 (306)•...
► Artikel lesen
20.08.Q-Linea AB: Q-linea appoints Malin Svensson as new Chief Financial Officer647Q-linea AB (publ) today announces that Malin Svensson has been appointed Chief Financial Officer and Investor Relations manager. She will assume her position no later than January 1, 2027 Malin Svensson...
► Artikel lesen
18.08.Q-Linea AB: Q-linea awarded a contract position with Premier, Inc.1.098Q-linea AB (publ) has been awarded a contract position with national group purchasing organization, Premier, Inc. Effective September 1, 2026, the new agreement allows the over 4,000 Premier member...
► Artikel lesen
10.08.Q-Linea AB: Q-linea Announces ASTar Contract With Large Health System in the U.S. Mid-Atlantic Region886Q-linea AB (publ) announces today that it has signed a contract with a major U.S. health system in the mid-Atlantic region for deployment of its ASTar® rapid antimicrobial susceptibility testing (AST)...
► Artikel lesen
10.07.Q-Linea AB: Interim report January 1 - June 30 20261.220FDA decision sets up for growth in U.S. FDA clearance for expanded U.S. menu combined with encouraging progress across Europe and focus organisation, positions Q-linea for growth during the second half...
► Artikel lesen
Q-LINEA Aktie jetzt für 0€ handeln
29.05.Q-Linea AB: Annika Blondeau Henriksson new interim CFO579Q-linea AB (publ) (OMX: QLINEA) today announces that the company has hired Annika Blondeau Henriksson as CFO and IR. Annika takes office on June 15, 2026, when she succeeds Christer Samuelsson, who...
► Artikel lesen
27.05.Q-linea AB: Bulletin From Annual General Meeting In Q-linea AB (publ)390The annual general meeting of Q-linea AB (publ) (the "Company"), reg. no. 556729-0217, was held on 27 May 2026 in Uppsala, at which the shareholders mainly passed the following resolutions. All resolutions...
► Artikel lesen
30.04.Q-Linea AB: Interim report January - March 2026461Growing recurring income and increased market activity within rapid AST First quarter: 1 January-31 March 2026Income from sales of consumables amounted to SEK 1.4 (0.9) million, an increase of approx....
► Artikel lesen
16.04.Q-Linea AB: Q-linea announces FDA clearance of expanded ASTar blood testing menu673Q-linea AB (publ) (OMX: QLINEA) today announces the company has received 510(k) clearance from the US FDA for its expanded ASTar® Gram-negative Blood Culture menu. The expanded panel represents a significant...
► Artikel lesen
30.12.25Q-Linea AB: Q-linea signs first distribution agreement in South Asia548Q-linea AB (publ) (OMX: QLINEA today announces the signing of its first distribution agreement in South Asia, marking an important milestone in the company's global expansion strategy. The agreement...
► Artikel lesen
23.12.25Q-Linea AB: Q-linea announces first two US hospital systems' clinical implementation of ASTar314Q-linea AB (Publ) (OMX: QLINEA) announces the clinical implementation of the first US ASTar instruments at UI (University of Iowa) Health Care and a large healthcare system in Texas. UI Health Care...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1